Prime Medicine, Inc. Common Stock (PRME) - Total Liabilities
Based on the latest financial reports, Prime Medicine, Inc. Common Stock (PRME) has total liabilities worth $209.23 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of Prime Medicine, Inc. Common Stock to evaluate the company's liquid asset resilience ratio.
Prime Medicine, Inc. Common Stock - Total Liabilities Trend (2019–2025)
This chart illustrates how Prime Medicine, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see PRME total assets.
Prime Medicine, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Prime Medicine, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Musti Group Oyj
HE:MUSTI
|
Finland | €288.33 Million |
|
Batisoke Soke Cimento Sanayi TAS
IS:BSOKE
|
Turkey | TL3.94 Billion |
|
Rusoro Mining Ltd
V:RML
|
Canada | CA$416.29 Million |
|
WPG (Shanghai) Smart Water Public Co. Ltd
SHG:603956
|
China | CN¥1.24 Billion |
|
Hongsheng Heat Exchanger Mnfg
SHG:603090
|
China | CN¥356.82 Million |
|
Shandong Sunway Petrochemical Engineering Co Ltd
SHE:002469
|
China | CN¥734.84 Million |
|
Invesco Value Municipal Income Closed Fund
NYSE:IIM
|
USA | $311.98 Million |
|
E&R Engineering
TWO:8027
|
Taiwan | NT$1.49 Billion |
Liability Composition Analysis (2019–2025)
This chart breaks down Prime Medicine, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See net asset quality index of Prime Medicine, Inc. Common Stock to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.05 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 5.26 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.84 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Prime Medicine, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Prime Medicine, Inc. Common Stock (2019–2025)
The table below shows the annual total liabilities of Prime Medicine, Inc. Common Stock from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $221.87 Million | +53.69% |
| 2024-12-31 | $144.36 Million | +137.51% |
| 2023-12-31 | $60.78 Million | +38.00% |
| 2022-12-31 | $44.04 Million | -29.30% |
| 2021-12-31 | $62.30 Million | +192.35% |
| 2020-12-31 | $21.31 Million | +191.58% |
| 2019-12-31 | $7.31 Million | -- |
About Prime Medicine, Inc. Common Stock
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder ca… Read more